Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: Nine standard SEER registries, 1975-2006

• Published in: Pediatric blood & cancer 2011-01, Vol.56 (1), p.50-57
• Main Authors: Navalkele, Pournima, O'Dorisio, M Sue, O'Dorisio, Thomas M., Zamba, Gideon K.D., Lynch, Charles F.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Child; Child, Preschool; children; Female; Humans; Incidence; Infant; Infant, Newborn; Male; neuroblastoma; Neuroblastoma - epidemiology; Neuroblastoma - mortality; neuroendocrine tumors; Neuroendocrine Tumors - epidemiology; Neuroendocrine Tumors - mortality; Prevalence; Prognosis; Registries; SEER; SEER Program; Survival Analysis; Survival Rate; Tissue Distribution; Young Adult
• ISSN: 1545-5009; 1545-5017; 1545-5017
• DOI: 10.1002/pbc.22559

Background The incidence, survival, and prevalence of neuroendocrine tumors (NETs) in children were determined as a first step in improving diagnosis and therapy. Outcomes were compared with neuroblastoma, a pediatric malignancy that shares several biomarkers. Methods Incidence rates, observed survival rates and 31‐year limited duration prevalence counts were obtained from SEER*Stat for diagnosis years 1975 to 2006. These rates were compared between and within NETs and neuroblastoma for demographic and tumor‐related variables from nine standard SEER registries for ages 0–29 years. Multivariate Cox regression was performed to identify prognostic factors for survival in NETs. Results The number of NETs was 1,073 compared to 1,664 neuroblastomas. The most common NET sites were lung, breast, and appendix. NET 5‐year observed survival rates increased from 83% between 1975 and 1979 to 84% for the 2000–2006 period, while analogous neuroblastoma survival rates steadily increased from 45–73%. Five‐year observed survival was less than 30% in females with NETs of the cervix and ovary. The estimated 31‐year limited duration prevalence for NETs as of January 1, 2006 in the U.S. population was 7,724 compared to 9,960 for neuroblastomas. Age‐adjusted multivariate Cox Regression demonstrated small cell histology, primary location in the breast, and distant stage as major predictors of decreased survival. Conclusions While survivorship has significantly increased for neuroblastoma, those diagnosed with NETs have shown no increase in survival during this 31‐year period. NETs constitute an unrecognized cancer threat to children and young adults comparable to neuroblastoma in both number of affected persons and disease severity. Pediatr Blood Cancer. 2010;56:50–57. © 2010 Wiley‐Liss, Inc.